Across its top 14 institutional holders, BRNS's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 26/100, avg. turnover score 32/100).

Quarterly Activity

Recent Activity

+$286.7K

Total Buy Value

$4.6K

Total Sell Value

New buy1

Trim1

Add3

Sold out1

Net Buyers

Net Sellers

Smart Money Convergence

BRNS does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/stocks/BRNS

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-02

2026-07-02

Barinthus Biotherapeutics held its 2026 Annual General Meeting on July 2, 2026. Shareholders approved all proposals, including the re-election of directors Karen T. Dawes and Anne M. Phillips, the reappointment of PricewaterhouseCoopers as auditor, and an advisory vote on executive compensation. Separately, the company disclosed that Nasdaq granted an additional 180-day extension until December 28, 2026 to regain compliance with the $1.00 minimum bid price for its American Depositary Shares. As a result, the listing of the ADSs was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective July 2, 2026.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

91864C107

FAQ

Who are the top institutional investors holding BARINTHUS BIOTHERAPEUTICS PL (BRNS)?

Major stakeholders currently include M&g PLC ($5.2M), HSG Holding Ltd ($1.2M), GLR Partners, LLC ($707.5K). Based on the latest 13F filings, there are a total of 14 tracked investment funds and institutions maintaining positions in BRNS.

What is the overall institutional sentiment toward BRNS recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $40.4M, driven by 4 managers accumulating shares while 2 reduced their exposure.

Which institutions have been selling or reducing their BRNS positions?

In the latest period, 1 funds trimmed their holdings, and 1 managers completely exited their positions. The aggregate reported sell value was $4.6K.

Are there any notable investors adding BRNS to their portfolios?

Yes, buying activity remains notable. 1 institutions opened new positions in {ticker}, and 3 existing holders added to their shares. The total reported buy value for the quarter amounted to $286.7K.